Despite numerous molecules being validated in clinical trials, such as CEA, CD133, MUC1, GCC19 and others [31–33], the therapeutic outcomes of CAR-T cells in CRC have not been as favorable as those observed in hematologic malignancies, with the objective response rates ranging from 20% to 40% [31, 33]. This evidence concerns the gene PROM1 and hematologic disorder.